Prostate Cancer
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).
August 21, 2024
Prostate-Specific Antigen Screening and Prostate Cancer Mortality: An Emulation of Target Trials in US Medicare.
August 21, 2024
Clinical decision making in prostate cancer care-evaluation of EAU-guidelines use and novel decision support software.
August 21, 2024
Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer.
August 21, 2024
Long noncoding RNA EPCART regulates translation through PI3K/AKT/mTOR pathway and PDCD4 in prostate cancer.
August 20, 2024
Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate.
August 19, 2024
Evaluating the added value of concurrent contrast-enhanced diagnostic CT for PSMA-PET/CT Interpretation.
August 19, 2024
Understanding and Addressing Prostate Cancer Disparities in Diagnosis, Treatment, and Outcomes Among Black Men.
August 19, 2024
Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer.
August 16, 2024